Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. reports news on its global diversified pharmaceutical business, including financial results, guidance, debt refinancing activity and updates from its operating businesses. The company develops, manufactures and markets products in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health through its controlling interest in Bausch + Lomb.
Recurring company updates include Salix gastroenterology programs, Ortho Dermatologics skincare and patient-support initiatives, Solta Medical aesthetic device launches, and quarterly performance for Bausch Health excluding Bausch + Lomb. News also covers product availability, regulatory clearances for medical aesthetic devices, clinical-program disclosures and capital-structure actions.
Bausch Health (NYSE:BHC) said Executive Vice President and CFO Jean-Jacques (JJ) Charhon and other management will attend the J.P. Morgan Global Leveraged Finance Conference in Miami Beach, Florida, from March 2–4, 2026 to meet with investors. This is a management investor engagement announcement.
Bausch Health (NYSE: BHC) and its gastroenterology business Salix opened applications for the 2026 Salix Gastrointestinal Health Scholars Program. The program will award 10 scholarships of up to $10,000 to students living with GI disease for the 2026–2027 academic year. Applications close May 6, 2026, and recipients will be notified in summer 2026. Awards include undergraduate, graduate, and working/single-parent categories. Applicants must submit an online application, references, and an essay about their GI condition and a health care provider's role. More details and eligibility are available at the Salix scholarship webpage.
Bausch Health (NYSE:BHC) announced results from the global Phase 3 RED-C program studying amorphous-rifaximin SSD for primary prevention of hepatic encephalopathy in adults with liver cirrhosis on Jan 23, 2026.
The trials were safe and well-tolerated but did not meet the primary endpoint. Management said it is reviewing the full dataset to determine potential new development opportunities and thanked patients, investigators, and research teams. Bausch Health reaffirmed its commitment to hepatology and other therapeutic areas.
Bausch Health (NYSE: BHC) will release its fourth quarter and full year 2025 financial results after market close on Wednesday, February 18, 2026. The company will host a live conference call and webcast at 5:00 p.m. U.S. EST to discuss results and provide a business update. Presentation materials and a replay of the call will be made available on the company's Investor Relations website prior to and after the call.
Bausch Health (NYSE:BHC) announced that CEO Thomas J. Appio will participate at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2026. Executive attendees include EVP/CFO Jean-Jacques Charhon and EVP/CMO & Head of R&D Jonathan Sadeh, M.D..
A live audio webcast will be accessible via the company's Investor Relations website at http://ir.bauschhealth.com/events-and-presentations, with a replay available after the event. Time: 3:45 p.m. PT / 6:45 p.m. ET.
Bausch Health (NYSE:BHC) announced final results and expiration of exchange offers for its outstanding 4.875% and 11.00% Senior Secured Notes due 2028. The offers expired on December 23, 2025. Holders validly tendered an aggregate of $2.7 billion of existing notes; the Offerors accepted existing notes resulting in approximately $1.6 billion principal amount of new 10.00% Senior Secured Notes due 2032, with settlement currently expected on December 26, 2025. The New Notes are unregistered in the U.S. and Canada and will be issued pursuant to the exchange terms described in the exchange offer memorandum.
Bausch Health (NYSE:BHC) announced early results of exchange offers to swap its outstanding 4.875% and 11.00% senior secured notes due 2028 for up to $1.6 billion aggregate principal of new 10.00% senior secured notes due 2032 issued by subsidiary 1261229 B.C. Ltd.
As of 5:00 p.m. ET on December 8, 2025, holders validly tendered $2,690,016,000 of existing notes, and the company expects to issue approximately $1,600 million of New Notes after applying the Maximum Notes Amount and proration. The Withdrawal Deadline passed on December 8; the Offers expire at 5:00 p.m. ET on December 23, 2025, with settlement expected within three business days after expiration.
Bausch Health (NYSE:BHC) announced that its aesthetic business, Solta Medical, completed the acquisition of Wuhan Shibo Zhenmei Technology Co., Ltd., the Shibo group's aesthetics distribution business, effective December 1, 2025. The Shibo group, a distribution partner for more than a decade, becomes a wholly owned Solta Medical subsidiary in China and assumes full responsibility for distributing Solta Medical products, including Thermage FLX.
The transaction is intended to deepen local presence, provide direct customer insight, speed market execution, and support growing demand for aesthetic treatments in China.
Bausch Health (NYSE:BHC) commenced offers on November 24, 2025 to exchange up to $1.6 billion aggregate principal of its outstanding 4.875% and 11.00% Senior Secured Notes due 2028 for new 10.00% Senior Secured Notes due 2032 issued by a wholly owned subsidiary.
Key terms: Exchange Consideration per $1,000 is $787.50 (4.875% notes) and $920.00 (11.00% notes); an Early Exchange Premium $100 per $1,000 applies for tenders by Dec 8, 2025; offers expire Dec 23, 2025. New Notes will be fungible with the issuer's existing 10.00% notes due 2032 and are subject to eligibility, customary conditions and a transaction support agreement covering ~$1,545 million of existing notes.
Bausch Health (NYSE:BHC) said Jean-Jacques Charhon, executive vice president and chief financial officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference in Coral Gables, Florida on December 2, 2025.
The session is scheduled for 10:50 a.m. – 11:10 a.m. ET and a live audio webcast will be available via the company’s Investor Relations website at http://ir.bauschhealth.com/events-and-presentations. A replay will be posted on the investor site after the event.